市场调查报告书
商品编码
1284073
到 2028 年的电子皮肤贴片市场预测-按产品、组件、传感器、产品类型、销售渠道、分销渠道、应用和地区分列的全球分析Electronic Skin Patch Market Forecasts to 2028 - Global Analysis By Product, By Component, By Sensor, By Type, By Sales Channel, By Distribution Channel, By Application and By Geography |
根据 Stratistics MRC,2022 年全球电子皮肤贴片市场将达到 82.7 亿美元,预测期内復合年增长率为 22.5%,预计 20.28 亿美元达到 279.5 亿美元.
皮肤贴片通过将它们贴在皮肤上来使用。 电子元件集成了传感器、执行器、处理器和通信等电子功能,使设备能够交互并变得“智能”。 皮肤贴片在许多方面都可以作为理想的可穿戴电子产品,以最轻的重量和最高的舒适度提升佩戴者的体验。
根据世界卫生组织发布的一份报告,2016年有4.22亿成年人患有糖尿病,而且这一数字预计还会增加,从而为电子皮肤贴片市场提供了机会。。
电子皮肤由于具有自愈性和柔韧性等优点,正在得到越来越广泛的应用。 合成皮肤接近人类感官,可用于各种健康监测技术。 由于其最重要的特性、敏感性和灵活性,人体皮肤在可穿戴技术中是独一无二的。 此外,越来越多的产品发布和 FDA 的快速批准正在推动市场增长。 例如,2018 年 5 月,FDA 批准了 MC10, Inc. 的 BioStamp nPoint 系统。
由于传统贴片的缺点,光伏系统越来越多地用于皮肤贴片和传感器。 传统的皮肤贴片有很多局限性,例如需要为设备充电,因此难以同时监测多人的健康状况。 此外,湿度等环境因素会降低电子皮肤贴片的性能,限制其适用性并製约市场扩张。
在预测期内,市场预计将受益于公众日益增强的健身导向。 电子皮肤贴片有望在医疗保健领域发挥作用,因为它们只需使用粘合剂即可监测生理过程,而无需进行侵入性治疗。 然而,消费者对可穿戴电子领域电子皮肤解决方案的需求不断增长以及技术进步预计将提振市场。
限制市场扩张的主要障碍。 初始成本高、设计困难、缺乏数据安全性和不兼容性阻碍了电子皮肤贴片的采用。
COVID-19 疫情引发了全球性问题。 世界已经完全停滞,许多企业都在为维持利润、失业和经济危机而苦苦挣扎。 医疗保健行业受到患者激增和护理不足的沉重打击。 随着死亡人数的增加,个人恐慌情况变得更糟。 贸易停滞不前,衣食住行困难重重。 由于封锁和业务关闭,COVID-19 大流行对全球电子皮肤贴片行业产生了不利影响。 供应炼和分销链受到限制,导致公司蒙受损失。
心血管监测预计在预测期内将占据最大的市场份额,因为心血管监测对于运动员来说非常重要,因为马拉松跑很多公里超过了人体的能力。 对于运动员来说,监测心肺健康对于跑得更好至关重要。 包括心率、前负荷、收缩力和后负荷在内的四个因素相互关联以产生心臟功能。
在预测期内,由于可穿戴电子设备与人体皮肤直接接触,会因人体运动而发生伸长和扭曲等各种变形,因此市场对可伸缩电路的需求有望增长身体。增加。 可伸缩电路可以为电子皮肤贴片提供广泛的功能可能性,例如定制的医疗保健监控和人体运动检测。 此外,使用可伸缩电路可以在不干扰日常生活的情况下测量各种生物信号。
预计在预测期内,欧洲将占据最大份额,因为传统的糖尿病监测方法使用葡萄糖试纸和手指点刺试验来监测血糖水平。 因此,在 2018 年 4 月,英国巴斯大学的科学家创造了一种粘性电子皮肤贴片,可以每 10-15 分钟测量一次血糖水平,以防止使用此类侵入性程序。。
在预测期内,亚太地区将主导全球电子皮肤贴片市场,因为技术进步能够创造出改进的电子皮肤贴片,而且该地区对设备的接受率很高。预计该地区将展示增长率最高。 此外,由于医疗保健基础设施的扩大,它预计将实现最高增长。 然而,增加研发业务的资金是该地区市场扩张的原因。
2023 年 4 月,雅培宣布完成对 Cardiovascular Systems, Inc. (CSI) 的收购,这是一家医疗设备公司,拥有用于治疗外周动脉和冠状动脉疾病的创新型粥样斑块切除术系统。. 通过此次收购,雅培将提供治疗血管疾病的补充解决方案。 CSI 的主要粥样斑块切除术系统准备血管并恢復血流,用于血管成形术和支架置入术。
2020年2月,Vital Connect宣布将部署可穿戴生物传感器“VitalPatch”,并配备远程监测平台,监测11种具有心律失常检测功能的生命体征测量。
2019 年 1 月,霍尔斯特中心宣布推出一次性健康贴片,用于测量与人类健康相关的生命体征。 这个突破性的健康补丁的一项重要技术改进是将各种传感器整合到 imec 的 MUSEIC V3 SoC 解决方案中。
According to Stratistics MRC, the Global Electronic Skin Patch Market is accounted for $8.27 billion in 2022 and is expected to reach $27.95 billion by 2028 growing at a CAGR of 22.5% during the forecast period. Skin patches are objects that can be used and are affixed to the skin. The electronic component entails integrating electronic features, including sensors, actuators, processors, and communication, which enable the devices to interact with one another and become "smart." Skin patches serve as the ideal wearable electronic gadgets in many aspects, enhancing the wearer with the least amount of weight and the highest level of comfort.
According to a report published by WHO, in 2016, there were 422 million adults suffering from diabetes and this number is expected to grow, thus providing opportunities for the electronic skin patch market.
Electronic skin is becoming more widely used as a result of its benefits, including self-healing and flexibility. Synthetic skin can be used in a wide range of health monitoring technologies as it closely resembles human sensory capacities. Human skin is unique among wearable technologies because of its sensitivity and flexibility, which are two of its most significant properties. Additionally, accelerating market growth are the rising number of product launches and rapid FDA approvals. For instance, the FDA approved the BioStamp nPoint system from MC10, Inc. in May 2018.
Photovoltaic systems are being utilized in skin patches and sensors more frequently due to the drawbacks of conventional patches. Traditional skin patches have a number of limitations, such as the need to charge the device, which has made it difficult for several individuals to monitor their health. Additionally, environmental factors like moisture and others degrade electronic skins patches, restricting their adaptability and constraining market expansion.
During the forecast period, the market is anticipated to benefit from the population's growing trend toward fitness. Electronic skin patches are expected to be advantageous for the healthcare sector because they do not require invasive treatments and only require an adhesive to monitor physiological processes. However, the market will expand as a result of rising consumer demand for electronic skin solutions in the wearable electronics sector as well as technological advancement.
There are significant obstacles that are limiting market expansion. The adoption of electronic skin patches is being hampered by issues like the high initial cost, challenging design, lack of data security, and lack of compatibility.
The COVID-19 epidemic sparked a problem that spread around the globe. Due to the complete shutdown of the world, many firms struggled to maintain revenue, which resulted in job losses and an economic crisis. The surge in patients and inadequate care caused the healthcare industry to suffer severely. The panic scenario among individuals grew worse as the death toll increased. Trades were slowed down or stopped altogether, and it was difficult to obtain the simplest necessities. Due to lockdowns and business closures, the COVID-19 pandemic had a negative effect on the global electronic skin patch industry. The supply and distribution networks were restricted, which resulted in losses for the company.
Cardiovascular monitoring is expected to hold the largest market share over the extrapolated period, because running marathons over many kilometers involves pushing beyond the capabilities of the human body, cardiovascular monitoring crucial for athletes. It has become crucial for athletes to monitor their heart function in order to better organize their runs. Four interconnected factors, including heart rate, preload, contractility, and afterload, result in cardiac function.
Due to wearable electronic devices attached in direct contact with human skin incorporating various deformations such as elongation and twisting resulting from human body movement, the demand for stretchable circuits is anticipated to have lucrative growth in the market throughout the forecast period. Stretchable circuits have the potential to enable a wide range of functional possibilities for electronic skin patches, including customized healthcare monitoring and human motion detection. Additionally, the stretchable circuits make it possible to measure a variety of biosignals without disrupting daily activities.
Because traditional methods of diabetes monitoring involve the use of glucose strips and finger-prick tests to monitor blood glucose levels, Europe is anticipated to have the largest share over the forecasted period. Thus, in April 2018, scientists from the University of Bath in the United Kingdom created an adhesive electronic skin patch that can measure blood glucose levels every 10-15 minutes in order to prevent the use of such invasive procedures.
Due to technological improvements that enabled the creation of improved electronic skin patches and a high acceptance rate for the devices in the area, the Asia-Pacific region was predicted to have the highest growth rate for the global market for electronic skin patches over the projected period. Furthermore, because of the expanding healthcare infrastructure, it is predicted to experience the highest growth. However, the rise in financing for R&D operations is accountable for the market expansion in this region.
Some of the key players in Electronic Skin Patch market include 3M, Abbott Laboratories, BioTelemetry, Inc., DexCom, Inc., Dialog Semiconductor, GE Healthcare, General Electric Company, Insulet Corporation, Intelesens Ltd., iRhythm Technologies Inc., Koninklijke Philips N.V., Leaf Healthcare Inc., Loreal SA, MC10, Medtronic, Plc., Nemaura Medical Inc., Omron Corporation, Physical Optics Corporation, Plastic Electronics GmbH, Quad industries SA, Senseonics Holding, Inc., Sensium Healthcare Ltd , Vitalconnect Inc. and VivaLNK.
In April 2023, Abbott announced it has completed the acquisition of Cardiovascular Systems, Inc. (CSI), a medical device company with an innovative atherectomy system used in treating peripheral and coronary artery disease. The transaction provides Abbott with a complementary solution for treating vascular disease. CSI's leading atherectomy system prepares vessels for angioplasty or stenting to restore blood flow.
In February 2020, VitalConnect made an announcement about the inclusion of arrhythmia detection functionality to its remote monitoring platform that deploys wearable biosensor, VitalPatch, to monitor the measurement of eleven vital signs.
In January 2019, Holst Centre announced the launch of a disposable health patch for taking measurements of vital signs associated with human health. An essential technology enhancement in this groundbreaking health patch is incorporating an extensive range of sensors into MUSEIC V3 SoC solution by imec.
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.